Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 6/20 | 0.38 |
| ▸ | SCN1A | P35498 | 7/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 7/20 | 0.35 |
| ▸ | SCN8A | Q9UQD0 | 7/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10249071 | 1.00 | HSD11B1 (0.38) | HSD11B1SCN1ASCN5ASCN8ACYP2C19 | |
| SCHEMBL5023711 | 1.00 | HSD11B1 (0.38) | HSD11B1SCN1ASCN5ASCN8ACYP2C19 | |
| SCHEMBL10249276 | 1.00 | HSD11B1 (0.38) | HSD11B1SCN1ASCN5ASCN8ACYP2C19 | |
| SCHEMBL14429506 | 0.87 | HSD11B1 (0.50) | HSD11B1SCN1ASCN5ASCN8AHTR6 | |
| SCHEMBL14429527 | 0.87 | HSD11B1 (0.50) | HSD11B1SCN1ASCN5ASCN8AHTR6 | |
| SCHEMBL14429526 | 0.87 | HSD11B1 (0.50) | HSD11B1SCN1ASCN5ASCN8AHTR6 | |
| SCHEMBL1690433 | 0.87 | HSD11B1 (0.48) | HSD11B1SCN1ASCN5ASCN8AMAPKAPK2 | |
| SCHEMBL21067564 | 0.87 | HSD11B1 (0.48) | HSD11B1SCN1ASCN5ASCN8AMAPKAPK2 | |
| SCHEMBL21408969 | 0.87 | HSD11B1 (0.38) | HSD11B1MAPKAPK2 | |
| SCHEMBL1606199 | 0.87 | HSD11B1 (0.48) | HSD11B1SCN1ASCN5ASCN8AMAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753736-B1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | AMGEN INC (US) | 2008-12-17 | — | — | EP | claimed |
| US-20070281938-A1 | Inhibitors of 11-Beta-Hydroxy Steroid Dehydrogenase Type 1 | AMGEN INC. | 2007-12-06 | — | — | US | claimed |
| CN-1964956-A | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AMGEN (US) | 2007-05-16 | — | — | CN | claimed |
| US-20060142357-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AMGEN INC. | 2006-06-29 | — | — | US | claimed |
| CN-1964956-B | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AMGEN INC | 2013-03-27 | — | — | CN | disclosed |
| US-20120010256-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB | 2012-01-12 | — | — | US | disclosed |
| US-20110082107-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | AMGEN INC. | 2011-04-07 | — | — | US | disclosed |
| US-7807700-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | AMGEN INC. (US) | 2010-10-05 | — | — | US | disclosed |
| EP-1753736-B1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | AMGEN INC (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20080045503-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AMGEN INC. | 2008-02-21 | — | — | US | disclosed |
| US-20070281938-A1 | Inhibitors of 11-Beta-Hydroxy Steroid Dehydrogenase Type 1 | AMGEN INC. | 2007-12-06 | — | — | US | disclosed |
| US-7253196-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | AMGEN, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| CN-1964956-A | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AMGEN (US) | 2007-05-16 | — | — | CN | disclosed |
| EP-1753736-A2 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | Amgen Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20060142357-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AMGEN INC. | 2006-06-29 | — | — | US | disclosed |
| WO-2005116002-A2 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | AMGEN INC. (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082107-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD3B1, HSD17B1 | HSD11B1 1/4885SCN1A 330/4885SCN5A 672/4885 |
| US-20080045503-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD3B1, HSD17B1 | HSD11B1 1/4885SCN1A 330/4885SCN5A 672/4885 |
| US-20060142357-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD3B1, HSD17B1 | HSD11B1 1/4885SCN1A 330/4885SCN5A 672/4885 |
| US-20120010256-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD3B1, HSD17B1 | HSD11B1 1/4885SCN1A 330/4885SCN5A 672/4885 |
| US-20070281938-A1 | Inhibitors of 11-Beta-Hydroxy Steroid Dehydrogenase Type 1 | HSD11B1, HSD3B1, HSD17B1 | HSD11B1 1/4885SCN1A 621/4885SCN5A 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.